176 related articles for article (PubMed ID: 36216845)
21. Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses.
Schellenbacher C; Kwak K; Fink D; Shafti-Keramat S; Huber B; Jindra C; Faust H; Dillner J; Roden RBS; Kirnbauer R
J Invest Dermatol; 2013 Dec; 133(12):2706-2713. PubMed ID: 23752042
[TBL] [Abstract][Full Text] [Related]
22. VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus.
Tumban E; Peabody J; Tyler M; Peabody DS; Chackerian B
PLoS One; 2012; 7(11):e49751. PubMed ID: 23185426
[TBL] [Abstract][Full Text] [Related]
23. A rationally designed flagellin-L2 fusion protein induced serum and mucosal neutralizing antibodies against multiple HPV types.
Zhang T; Chen X; Liu H; Bao Q; Wang Z; Liao G; Xu X
Vaccine; 2019 Jul; 37(30):4022-4030. PubMed ID: 31213378
[TBL] [Abstract][Full Text] [Related]
24. Impact of inhibitors and L2 antibodies upon the infectivity of diverse alpha and beta human papillomavirus types.
Kwak K; Jiang R; Wang JW; Jagu S; Kirnbauer R; Roden RB
PLoS One; 2014; 9(5):e97232. PubMed ID: 24816794
[TBL] [Abstract][Full Text] [Related]
25. A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9.
Zhai L; Peabody J; Pang YS; Schiller J; Chackerian B; Tumban E
Antiviral Res; 2017 Nov; 147():116-123. PubMed ID: 28939477
[TBL] [Abstract][Full Text] [Related]
26. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.
Tumban E; Muttil P; Escobar CA; Peabody J; Wafula D; Peabody DS; Chackerian B
Vaccine; 2015 Jun; 33(29):3346-53. PubMed ID: 26003490
[TBL] [Abstract][Full Text] [Related]
27. Adenovirus based HPV L2 vaccine induces broad cross-reactive humoral immune responses.
Vujadinovic M; Khan S; Oosterhuis K; Uil TG; Wunderlich K; Damman S; Boedhoe S; Verwilligen A; Knibbe J; Serroyen J; Schuitemaker H; Zahn R; Scheper G; Custers J; Vellinga J
Vaccine; 2018 Jul; 36(30):4462-4470. PubMed ID: 29914845
[TBL] [Abstract][Full Text] [Related]
28. Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?
Yadav R; Zhai L; Tumban E
Viruses; 2019 Dec; 12(1):. PubMed ID: 31877975
[TBL] [Abstract][Full Text] [Related]
29. A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types.
Huber B; Schellenbacher C; Jindra C; Fink D; Shafti-Keramat S; Kirnbauer R
PLoS One; 2015; 10(3):e0120152. PubMed ID: 25790098
[TBL] [Abstract][Full Text] [Related]
30. A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies.
Day PM; Pang YY; Kines RC; Thompson CD; Lowy DR; Schiller JT
Clin Vaccine Immunol; 2012 Jul; 19(7):1075-82. PubMed ID: 22593236
[TBL] [Abstract][Full Text] [Related]
31. Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate.
Nieto K; Weghofer M; Sehr P; Ritter M; Sedlmeier S; Karanam B; Seitz H; Müller M; Kellner M; Hörer M; Michaelis U; Roden RB; Gissmann L; Kleinschmidt JA
PLoS One; 2012; 7(6):e39741. PubMed ID: 22761884
[TBL] [Abstract][Full Text] [Related]
32. Prophylactic immunization with human papillomavirus vaccines induces oral immunity in mice.
Ahn J; Peng S; Hung CF; Roden RBS; Best SR
Laryngoscope; 2018 Jan; 128(1):E16-E20. PubMed ID: 28868617
[TBL] [Abstract][Full Text] [Related]
33. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice.
Nardelli-Haefliger D; Roden RB; Benyacoub J; Sahli R; Kraehenbuhl JP; Schiller JT; Lachat P; Potts A; De Grandi P
Infect Immun; 1997 Aug; 65(8):3328-36. PubMed ID: 9234794
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of specific humoral and cellular immune responses against the major capsid L1 protein of cutaneous wart-associated alpha-Papillomaviruses in solid organ transplant recipients.
Gaiser MR; Textor S; Senger T; Schädlich L; Waterboer T; Kaufmann AM; Süsal C; Pawlita M; Enk AH; Gissmann L; Lonsdorf AS
J Dermatol Sci; 2015 Jan; 77(1):37-45. PubMed ID: 25439730
[TBL] [Abstract][Full Text] [Related]
35. Spontaneous and Vaccine-Induced Clearance of Mus Musculus Papillomavirus 1 Infection.
Jiang RT; Wang JW; Peng S; Huang TC; Wang C; Cannella F; Chang YN; Viscidi RP; Best SRA; Hung CF; Roden RBS
J Virol; 2017 Aug; 91(15):. PubMed ID: 28515303
[TBL] [Abstract][Full Text] [Related]
36. A vaccine of L2 epitope repeats fused with a modified IgG1 Fc induced cross-neutralizing antibodies and protective immunity against divergent human papillomavirus types.
Chen X; Liu H; Zhang T; Liu Y; Xie X; Wang Z; Xu X
PLoS One; 2014; 9(5):e95448. PubMed ID: 24802101
[TBL] [Abstract][Full Text] [Related]
37. Optimization of multimeric human papillomavirus L2 vaccines.
Jagu S; Kwak K; Karanam B; Huh WK; Damotharan V; Chivukula SV; Roden RB
PLoS One; 2013; 8(1):e55538. PubMed ID: 23383218
[TBL] [Abstract][Full Text] [Related]
38. Mixed Bacteriophage MS2-L2 VLPs Elicit Long-Lasting Protective Antibodies against HPV Pseudovirus 51.
Yadav R; Zhai L; Kunda NK; Muttil P; Tumban E
Viruses; 2021 Jun; 13(6):. PubMed ID: 34200586
[TBL] [Abstract][Full Text] [Related]
39. Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines.
Schellenbacher C; Roden R; Kirnbauer R
J Virol; 2009 Oct; 83(19):10085-95. PubMed ID: 19640991
[TBL] [Abstract][Full Text] [Related]
40. In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine.
Namvar A; Bolhassani A; Javadi G; Noormohammadi Z
Sci Rep; 2019 Oct; 9(1):15225. PubMed ID: 31645650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
